Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Lowered to $290 at Oppenheimer on CRL for MDD

August 7, 2023 6:28 AM
Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $360.00) while maintaining a Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles